About Hermansky-Pudlak Syndrome
Hermansky-Pudlak syndrome is a multisystem disorder characterised by oculocutaneous albinism, a platelet storage pool defect, and the accumulation of ceroid lipofuscin in tissues. Pulmonary fibrosis, the leading cause of death, develops in adulthood and is most severe in individuals with HPS-1 and HPS-4 subtypes. The interstitial lung disease in HPS closely resembles idiopathic pulmonary fibrosis histologically, making subtype classification critical for both prognosis and trial eligibility.
Common Clinical Features
Clinical Trial Eligibility Tips
What to know before applying to Hermansky-Pudlak Syndrome trials.
Identify your HPS subtype (HPS-1 through HPS-10) before applying, as trials targeting pulmonary fibrosis often restrict enrolment to fibrosis-prone subtypes (HPS-1, HPS-4).
Bleeding risk from platelet dysfunction may disqualify patients from trials requiring invasive procedures such as bronchoscopy or biopsy; disclose platelet function test results upfront.
HRCT evidence of pulmonary fibrosis and recent PFTs are standard screening requirements; ensure imaging is within the trial's specified time window.
Patient Resources
Find recruiting Hermansky-Pudlak Syndrome trials
Search 500,000+ studies from ClinicalTrials.gov, filtered for Hermansky-Pudlak Syndrome. Updated daily.